Accelerated clearance of a second injection of PEGylated liposomes in mice.

We recently reported that the firstly injected PEGylated liposomes dramatically affected the rate of blood clearance of secondly injected PEGylated liposomes in rats in a time interval of injection dependent manner [J. Control. Release (2003)]. Mice are frequently used in evaluations of the therapeutic efficacy of PEGylated liposomal formulations, but the pharmacokinetics of repeatedly injected PEGylated liposomes in mice is not fully understood. In this study, therefore, we examined in mice the effect of the repeated injection of PEGylated liposomes on their pharmacokinetics. An intravenous pretreatment with PEGylated liposomes produced a striking change in the biodistribution of the second dose which was given several days after the first injection. The first dose resulted in a reduction in the circulation half-life of the second dose. The degree of alteration was dependent on the time interval between the injections. The rapid clearance of the second dose was strongly related to hepatic clearance (CLh). This finding suggests that a considerable increase in hepatic accumulation accounts for this phenomenon. But, no liver injury or an increase in the number of Kupffer cells were detected in histopathological evaluations. Collectively, although the multiple injections of the PEGylated liposomes had no obvious physical effects, such as inflammation, their pharmacokinetic behavior was clearly altered in mice. The results obtained here have important implications not only with respect to the design and engineering of liposomes for human use, but for evaluating the therapeutic efficacy of liposomal formulations in experimental animal models as well.

[1]  H. Harashima,et al.  Kinetic modeling of liposome degradation in blood circulation , 1993, Biopharmaceutics & drug disposition.

[2]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[3]  H. Harashima,et al.  Kinetic analysis of AUC-dependent saturable clearance of liposomes: Mathematical description of AUC dependency , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  D. Pode,et al.  Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.

[5]  F. Berr,et al.  A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  G. Hofstede,et al.  Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages , 1995, International journal of cancer.

[7]  B. Goins,et al.  Repeat Injection Studies of Technetium-99M-Labeled Peg-Liposomes in the Same Animal , 1998 .

[8]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[9]  J. Hainsworth,et al.  Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Oyen,et al.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  W. Oyen,et al.  Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. , 2001, The Journal of pharmacology and experimental therapeutics.

[12]  T. Ishida,et al.  Accelerated clearance of PEGylated liposomes in rats after repeated injections. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[13]  G. R. Bartlett Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[14]  K. Avgoustakis,et al.  Protein-induced CF release from liposomes in vitro and its correlation with the BLOOD/RES biodistribution of liposomes , 1998 .

[15]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[16]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. T. ten Kate,et al.  Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. , 1995, The Journal of antimicrobial chemotherapy.

[18]  G. Storm,et al.  Sterically stabilized amphotericin B-liposomes : toxicity and biodistribution in mice , 1995 .

[19]  H. Harashima,et al.  Biodistribution of liposomes and C3 fragments associated with liposomes: evaluation of their relationship. , 2000, International journal of pharmaceutics.

[20]  T. Allen LIPOSOME TARGETING IN ANIMAL MODELS: PROBLEMS AND OPPORTUNITIES , 1997 .

[21]  N. Brockmeyer,et al.  Fatal hepatic failure with liposomal doxorubicin , 1993, The Lancet.